Key result
Prehospital fibrinolysis for high-risk pulmonary embolism was associated with a 12-month mortality of 52%, compared to 76% in patients who did not receive fibrinolysis (p=0.06).
Why the study?
High-risk PE manifests as obstructive shock or cardiac arrest requiring immediate treatment, but survival and bleeding complications of prehospital fibrinolysis needed exploration.
Does prehospital intravenous fibrinolysis improve survival in patients with high-risk pulmonary embolism?
Observational (n=60)
No
Does prehospital intravenous fibrinolysis improve survival in patients with high-risk pulmonary embolism?
Absolute Event Rate: 52% vs 76%
p-value: p=0.06
Prehospital fibrinolysis for high-risk pulmonary embolism appears safe and may offer a survival benefit, though further randomized trials are needed.
Prehospital fibrinolysis for suspected high-risk PE requires caution given bleeding and mortality risks; leaves open its net benefit pending randomized trials.
OBJECTIVES High-risk pulmonary embolism (PE) manifests as obstructive shock or cardiac arrest and requires immediate treatment. Our aim was to explore survival and bleeding complications of prehospital fibrinolysis in the treatment of suspected high-risk PE.METHODS We collected patient data from the emergency medical services (EMS) registry of the Helsinki metropolitan area and the hospital database of Helsinki University Hospital between 2007 and 2019. The inclusion criteria were clinically suspected, high-risk PE treated with intravenous fibrinolysis by EMS. Diagnosis of PE was confirmed in all patients with imaging or by autopsy. Patients who did not receive prehospital fibrinolysis served as comparators.RESULTS The study included sixty patients. Twenty-three patients, 44% female, with a mean age of 57 years received prehospital fibrinolysis. Seventeen of those patients (74%) had suffered cardiac arrest and six patients (26%) had obstructive shock as the leading manifestation. Prehospital mortality was 35% (n = 8/23) and in-hospital mortality 27% (n = 4/15), for a total (prehospital + in-hospital) mortality rate of 52% (n = 12/23). All deaths were among patients presenting with cardiac arrest. Two patients had major bleeding complications, but none were fatal. All eleven fibrinolysis patients who were discharged alive from the hospital were still alive at a twelve-month follow-up. In comparison, there were 37 high-risk PE patients who did not receive fibrinolysis. They were older (mean, 72 years) and more likely to present with cardiac arrest (51%), and their 12-month mortality tended to be higher (76%) (p = 0.06).CONCLUSIONS Out-of-hospital high-risk PE is associated with high mortality. In this case-series, fibrinolysis appears to be safe. The possible survival benefit needs to be confirmed in further trials.
No takes yet. Share an insight, caveat, or question.
Harjola et al. (2025) conducted an observational in High-risk pulmonary embolism (n=60). Prehospital intravenous fibrinolysis vs. No prehospital fibrinolysis was evaluated on 12-month mortality (p=0.06). Prehospital fibrinolysis for high-risk pulmonary embolism was associated with a 12-month mortality of 52%, compared to 76% in patients who did not receive fibrinolysis (p=0.06).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: